Scholar Rock Holding (SRRK) stock: insider trades, news & valuation
Net selling
Close · Oct 9, 2026
$42.19
-0.0% on the day
+2.9% over 12 months
52-week range $27.92 – $60.04
Share price and insider trades
SRRK closeInsider buyInsider sale
Bought, 12 months$1.2M
Sold, 12 months$19.4M
Insiders buying1
Insiders selling13
Scholar Rock Holding insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $1.2M and 13 sold $19.4M of SRRK stock on the open market.
Get emailed when insiders cluster-buy stocks like SRRK
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
SRRK insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $923K | 13 |
| Q2 2026 | — | 0 | $3.1M | 4 |
| Q1 2026 | — | 0 | $9.2M | 18 |
| Q4 2025 | $20.0M | 9 | $6.2M | 3 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.5×Last 5 sessions
Insiders' paper profit+$2.4MOn all tracked purchases +11.9%
Summary
Over the past 12 months, 1 Scholar Rock Holding Corp insider reported open-market purchases totaling $1.2M, while 13 insiders reported sales totaling $19.4M. Among insiders with enough purchase history to measure, Srinivas Akkaraju (Director) has the highest Insider Score at 100. 22 of 38 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Jul 6SEC | Katie PengDirector | Sell Plan | 2,98836,759 held (−8%) | $53.56 | $160K | -21.2% | — |
| Jul 6SEC | Katie PengDirector | Sell Plan | 2,43734,322 held (−7%) | $54.25 | $132K | -22.2% | — |
| Jul 6SEC | Joshua ReedDirector | Sell Plan | 2,10520,466 held (−9%) | $53.50 | $113K | -21.1% | — |
| Jul 6SEC | Kristina BurowDirector | Sell Plan | 2,105115,605 held (−2%) | $53.49 | $113K | -21.1% | — |
| Jul 6SEC | Jeffrey S. FlierDirector | Sell Plan | 1,56829,341 held (−5%) | $53.53 | $84K | -21.2% | — |
| Jul 6SEC | Jeffrey S. FlierDirector | Sell Plan | 1,47027,871 held (−5%) | $54.24 | $80K | -22.2% | — |
| Jul 6SEC | Michael GilmanDirector | Sell Plan | 1,34660,709 held (−2%) | $53.54 | $72K | -21.2% | — |
| Jul 6SEC | Michael GilmanDirector | Sell Plan | 1,15559,554 held (−2%) | $54.23 | $63K | -22.2% | — |
| Jul 6SEC | Joshua ReedDirector | Sell Plan | 94819,518 held (−5%) | $54.28 | $51K | -22.3% | — |
| Jul 6SEC | Kristina BurowDirector | Sell Plan | 948114,657 held (−1%) | $54.28 | $51K | -22.3% | — |
| Jul 6SEC | Michael GilmanDirector | Sell Plan | 4359,511 held (−0%) | $54.81 | $2K | -23.0% | — |
| Jul 6SEC | Katie PengDirector | Sell Plan | 2134,301 held (−0%) | $54.96 | $1K | -23.2% | — |
| Jul 6SEC | Jeffrey S. FlierDirector | Sell Plan | 1527,856 held (−0%) | $54.88 | $823 | -23.1% | — |
| Apr 20SEC | David HallalCEO | Sell | 30,6151,639,034 held (−2%) | $49.57 | $1.5M | -14.9% | — |
| Apr 20SEC | Akshay VaishnawPresident | Sell | 12,246630,542 held (−2%) | $49.57 | $607K | -14.9% | — |
| Apr 20SEC | Vikas SinhaCFO | Sell | 10,410619,856 held (−2%) | $49.57 | $516K | -14.9% | — |
| Apr 20SEC | Keith WoodsCOO | Sell | 10,220620,055 held (−2%) | $49.57 | $507K | -14.9% | — |
| Feb 25SEC | Mo QatananiChief Scientific Officer | Sell Plan | 7,42799,502 held (−7%) | $46.94 | $349K | -10.1% | — |
| Feb 25SEC | Mo QatananiChief Scientific Officer | Sell Plan | 85798,645 held (−1%) | $47.86 | $41K | -11.8% | — |
| Feb 25SEC | Mo QatananiChief Scientific Officer | Sell Plan | 20098,445 held (−0%) | $48.48 | $10K | -13.0% | — |
| Feb 19SEC | Junlin HoGeneral Counsel | Sell | 9,580241,545 held (−4%) | $46.53 | $446K | -9.3% | — |
| Feb 19SEC | Caryn ParlavecchioChro | Sell | 9,035169,087 held (−5%) | $46.53 | $420K | -9.3% | — |
| Feb 19SEC | Mo QatananiChief Scientific Officer | Sell | 7,989106,929 held (−7%) | $46.53 | $372K | -9.3% | — |
| Feb 19SEC | Jing L. MarantzChief Medical Officer | Sell | 4,157126,012 held (−3%) | $46.53 | $193K | -9.3% | — |
| Jan 23SEC | Mo QatananiChief Scientific Officer | Sell Plan | 12,77985,660 held (−13%) | $46.85 | $599K | -9.9% | — |
| Jan 23SEC | Mo QatananiChief Scientific Officer | Sell Plan | 2,11998,439 held (−2%) | $45.87 | $97K | -8.0% | — |
| Jan 21SEC | Mo QatananiChief Scientific Officer | Sell | 8,406100,558 held (−8%) | $44.48 | $374K | -5.1% | — |
| Jan 21SEC | Junlin HoGeneral Counsel | Sell | 8,016214,553 held (−4%) | $44.48 | $357K | -5.1% | — |
| Jan 21SEC | Caryn ParlavecchioChro | Sell | 6,600148,864 held (−4%) | $44.48 | $294K | -5.1% | — |
| Jan 21SEC | Jing L. MarantzChief Medical Officer | Sell | 5,79895,687 held (−6%) | $44.48 | $258K | -5.1% | — |
| Jan 16SEC | Mo QatananiChief Scientific Officer | Sell Plan | 13,112108,964 held (−11%) | $45.20 | $593K | -6.7% | — |
| Jan 15SEC | David HallalCEO | Sell | 57,4501,541,645 held (−4%) | $42.70 | $2.5M | -1.2% | — |
| Jan 15SEC | Akshay VaishnawPresident | Sell | 20,438595,767 held (−3%) | $42.70 | $873K | -1.2% | — |
| Jan 15SEC | Vikas SinhaCFO | Sell | 16,755583,245 held (−3%) | $42.70 | $715K | -1.2% | — |
| Jan 15SEC | Keith WoodsCOO | Sell | 16,746583,254 held (−3%) | $42.70 | $715K | -1.2% | — |
| Dec 18SEC | Katie PengDirector | Sell Plan | 72633,188 held (−2%) | $43.88 | $32K | -3.9% | — |
| Dec 18SEC | Katie PengDirector | Sell Plan | 28032,908 held (−1%) | $44.63 | $12K | -5.5% | — |
| Dec 16SEC | Srinivas AkkarajuDirector | Buy | 12,796513,235 held (+3%) | $39.31 | $503K | +7.3% | 100 |
| Dec 16SEC | Srinivas AkkarajuDirector | Buy | 12,400525,635 held (+2%) | $40.18 | $498K | +5.0% | 100 |
| Dec 16SEC | Srinivas AkkarajuDirector | Buy | 4,403530,038 held (+1%) | $40.97 | $180K | +3.0% | 100 |
| Dec 5SEC | Mo QatananiChief Scientific Officer | Sell Plan | 136,462108,964 held (−56%) | $45.21 | $6.2M | -6.7% | — |
| Oct 7SEC | Srinivas AkkarajuDirector | Buy | 319,700387,414 held (+472%) | $37.42 | $12.0M | +12.7% | 100 |
| Oct 7SEC | Srinivas AkkarajuDirector | Buy | 80,863486,691 held (+20%) | $38.68 | $3.1M | +9.1% | 100 |
| Oct 7SEC | Srinivas AkkarajuDirector | Buy | 56,70367,714 held (+515%) | $36.74 | $2.1M | +14.8% | 100 |
| Oct 7SEC | Srinivas AkkarajuDirector | Buy | 18,414405,828 held (+5%) | $37.89 | $698K | +11.3% | 100 |
| Oct 7SEC | Srinivas AkkarajuDirector | Buy | 13,748500,439 held (+3%) | $39.52 | $543K | +6.8% | 100 |
| Oct 7SEC | Srinivas AkkarajuDirector | Buy | 11,011new position | $35.61 | $392K | +18.5% | 100 |
Insiders at Scholar Rock Holding Corp
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Srinivas AkkarajuDirector | $20.0M | — | Dec 16, 2025 | 100 |
| Mo QatananiChief Scientific Officer | — | $8.6M | Feb 25, 2026 | — |
| David HallalCEO | — | $4.0M | Apr 20, 2026 | — |
| Akshay VaishnawPresident | — | $1.5M | Apr 20, 2026 | — |
| Vikas SinhaCFO | — | $1.2M | Apr 20, 2026 | — |
| Keith WoodsCOO | — | $1.2M | Apr 20, 2026 | — |
| Junlin HoGeneral Counsel | — | $802K | Feb 19, 2026 | — |
| Caryn ParlavecchioChro | — | $714K | Feb 19, 2026 | — |
| Jing L. MarantzChief Medical Officer | — | $451K | Feb 19, 2026 | — |
| Katie PengDirector | — | $338K | Jul 6, 2026 | — |
| Jeffrey S. FlierDirector | — | $164K | Jul 6, 2026 | — |
| Joshua ReedDirector | — | $164K | Jul 6, 2026 | — |
| Kristina BurowDirector | — | $164K | Jul 6, 2026 | — |
| Michael GilmanDirector | — | $137K | Jul 6, 2026 | — |
SRRK stock: common questions
Are Scholar Rock Holding Corp insiders buying SRRK stock?
In the past 12 months, 1 insiders reported open-market purchases of SRRK worth $1.2M. The latest was Director Srinivas Akkaraju bought $503K of SRRK at $39.31.
Are Scholar Rock Holding Corp insiders selling SRRK stock?
13 insiders reported sales worth $19.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is SRRK's 52-week range?
Over the past year SRRK has traded between $27.92 and $60.04. It last closed at $42.19 on Oct 9, 2026.